A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. (2012)

First Author: Guzauskas GF
Attributed to:  North West HTMR funded by MRC


No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/clpt.2011.303

PubMed Identifier: 22453194

Publication URI: http://europepmc.org/abstract/MED/22453194

Type: Journal Article/Review

Volume: 91

Parent Publication: Clinical pharmacology and therapeutics

Issue: 5

ISSN: 0009-9236